<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":2671,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
Alcon Research, Ltd. v. Apotex Inc., 687 F.3d 1362, 103 U.S.P.Q.2d 1737 (Fed. Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/536878859f55c280da77bc1b3c141737'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/536878859f55c280da77bc1b3c141737'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/X1I31GA003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1I31GA003">Previous Result: <span>Dailey v. Astrue, No. CIVIL ACTION NO.: ...</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/X1I31H8003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1I31H8003">Next Result: <span>Donahoe v. Arpaio, No. CV 10-02756-PHX-N...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation positive" title="Positive"></div>
<div class='title left' title='Alcon Research, Ltd. v. Apotex Inc., 687 F.3d 1362, 103 U.S.P.Q.2d 1737 (Fed. Cir. 2012), Court Opinion'>
Alcon Research, Ltd. v. Apotex Inc., 687 F.3d 1362, 103 U.S.P.Q.2d 1737 (Fed. Cir. 2012), Court...
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>Alcon Research, Ltd. v. Apotex Inc., 687 F.3d 1362, 103 U.S.P.Q.2d 1737 (Fed. Cir. 2012), Court Opinion</div>
<div class='docId'>X1I2VS4003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>Alcon Research, Ltd. v. Apotex Inc.</div>
<div class='displayCitation'>103 U.S.P.Q.2d 1737</div>
<div class='displayCitation'>2012 BL 199915</div>
<div class='displayCitation'>2012 BL 201384</div>
<div class='displayCitation'>687 F.3d 1362</div>
<div class='displayCitation'>bna a0d3z6a9c2</div>
<div class='displayCitation'>bna a0d4f2r3m0</div>
<div class='displayCitation'>wkffecase:26263490</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1I2VS4003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="Alcon Research, Ltd. v. Apotex Inc., 687 F.3d 1362, 103 U.S.P.Q.2d 1737 (Fed. Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="Alcon Research, Ltd. v. Apotex Inc." />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/536878859f55c280da77bc1b3c141737/document/X1I2VS4003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1I2VS4003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1I2VS4003" /><input id="title" name="title" type="hidden" value="Alcon Research, Ltd. v. Apotex Inc., 687 F.3d 1362, 103 U.S.P.Q.2d 1737 (Fed. Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="POSITIVE" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="536878859f55c280da77bc1b3c141737" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1I2VS4003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="true" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2F%35%33%36%38%37%38%38%35%39f%35%35c%32%38%30da%37%37bc%31b%33c%31%34%31%37%33%37%2Fdocument%2FX%31I%32VS%34%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/536878859f55c280da77bc1b3c141737/bcite/X1I2VS4003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/536878859f55c280da77bc1b3c141737/bcite/X1I2VS4003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/536878859f55c280da77bc1b3c141737/bcite/X1I2VS4003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/536878859f55c280da77bc1b3c141737/related_content/X1I2VS4003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1721204080643";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,ReporterOfDecisions,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">687 F.3d 1362</div>
<div class="cite" data-cite-type="ReporterOfDecisions">103 U.S.P.Q.2d 1737</div>
<div class="cite" data-cite-type="DocketNumber">2011-1455</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 201384</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">U.S.P.Q.2d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">***</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Federal Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
ALCON RESEARCH, LTD. (Formerly Known As Alcon Manufacturing, Ltd.), Alcon
Laboratories, Inc., and Kyowa Hakko Kirin Co. Ltd., Plaintiffs-Appellees, v.
APOTEX INC. and Apotex Corp., Defendants-Appellants.
</center></p>
<hr align="center" width="65%">
<p><center>
No. 2011-1455.
</center></p>
<p><center>
August 8, 2012.
<span CLASS="page_no" data-cite="103 uspq 2d 1738" data-cite-type="ReporterOfDecisions" data-cite-pageno="1738" data-primary-citation="103 U.S.P.Q.2d 1737">[**1738]</span> </center></p>
<div class="headnotesToggle clearfix"><button id="toggle_headnotes_button" class="bootstrap skinButton sourceButton wide right hideSource" data-target="#headnotes_container"><span>Hide Headnotes</span></button></div>
<div class="headnotesContainer" id="headnotes_container">
<div class="headnotesContainerTitle">BNA Headnotes</div>
<div class="headnoteTitle"><a href="http://www.bloomberglaw.com/document/1475619602000128">U.S. Patents Quarterly</a></div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">PATENTS</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_924800" href="#headnote_ref_pq2-dec_924800">[1]</a> <span>Patentability/Validity &mdash; Construction of claims </span> <a href="http://www.bloomberglaw.com/document/1721204080643/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.03">&#9658;115.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_1" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_1" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patent construction &mdash; Claims &mdash; Broad or narrow </span> <a href="http://www.bloomberglaw.com/document/1721204080643/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=125.1303" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="125.1303">&#9658;125.1303</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_2" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_2" class="headnoteContent"></div>
<div class="headnote_text">
Claims directed to method of treating human eye allergies by stabilizing conjunctival mast cells must be construed, for purposes of comparison with disclosure of prior art, as claiming entire concentration range of 0.0001 to 5 % w/v recited in dependent claim, since dependent claim cannot be broader than claim from which it depends and must incorporate all limitations of claim to which it refers, since dependent claims of patent in suit must necessarily meet independent claim's limitations of being &ldquo;therapeutically effective&rdquo; for treating allergic eye disease by stabilizing conjunctival mast cells, and since independent claim, therefore, must cover at least range of 0.0001 to 5 % w/v; if dependent claims were construed as covering broader range than range that is operative to stabilize mast cells, they would be invalid in their entireties, not &ldquo;operative&rdquo; but at &ldquo;narrower concentration&rdquo; than claimed range, since patentee claiming concentration range cannot simply disavow invalid portion of claim and keep valid portion. </div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_924801" href="#headnote_ref_pq2-dec_924801">[2]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; Particular inventions </span> <a href="http://www.bloomberglaw.com/document/1721204080643/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.03">&#9658;115.0903.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_3" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_3" class="headnoteContent"></div>
<div class="headnote_text">
Federal district court erred in ruling that claims of patent directed to method of treating human eye allergies by stabilizing conjunctival mast cells would not have been obvious over prior art reference that discloses treating eye allergies in guinea pigs using eye drops with olopatadine concentrations ranging from 0.0001 to 0.01 % w/v, since this range overlaps with concentrations covered by asserted claims, since district court found that animal tests are predictive of compound's anti-histaminic activity and topical ocular availability in humans, but despite this factual finding, district court refused to look beyond motivation articulated in patent, and erroneously concluded that there was no motivation to adapt formulation of reference for use in treating human allergic eye disease, since court's finding that prior art did not teach that olopatadine would stabilize human conjunctival mast cells, and taught away from using olopatadine for this purpose, is not clearly erroneous, but does not constitute only motivation to arrive at claimed invention, since lack of explicit instruction that olopatadine is safe for human ophthalmic use would not impede skilled artisan's reasonable expectation of success for adapting reference's formulation for same use in human eye, since patent defines mast-cell stabilization as property that is necessarily present at concentrations claimed therein, and reference thus meets claims' &ldquo;stabilizing conjunctival mast cells&rdquo; limitation, and since, after balancing objective evidence against strong evidence of obviousness, clear and convincing evidence supports obviousness finding. </div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_924802" href="#headnote_ref_pq2-dec_924802">[3]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; Particular inventions </span> <a href="http://www.bloomberglaw.com/document/1721204080643/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.03">&#9658;115.0903.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_4" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_4" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patentability/Validity &mdash; Obviousness &mdash; Commercial success </span> <a href="http://www.bloomberglaw.com/document/1721204080643/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0908" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0908">&#9658;115.0908</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_5" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_5" class="headnoteContent"></div>
<div class="headnote_text">
Federal district court did not err in ruling that asserted claims of patent directed to method of treating human eye allergies by stabilizing conjunctival mast cells would not have been obvious over prior art reference that discloses treating eye allergies in guinea pigs using eye drops with olopatadine concentrations ranging from 0.0001 % w/v to 0.01 % w/v, since asserted claims are limited to olopatadine concentrations of about 0.1 % w/v, and reference does not disclose this limitation, since person of ordinary skill in art would not have had reasonable expectation of success for increasing highest dosage used in reference by order of magnitude, and would have been concerned that olopatadine might be biphasic at increased concentration, since person of ordinary skill would have known that olopatadine cannot simply be substituted for active ingredient of ophthalmic formulation disclosed in second reference without adjusting concentration, and since objective evidence supports nonobvious holding and merits of invention, in view of district court's findings that commercial embodiment of patent was &ldquo;outstanding commercial success.&rdquo;</div>
</div>
</div>
<script type="text/javascript">
					jQuery(function($) {
						$('#toggle_headnotes_button').click(document_toggleHeadnoteVisibility);
					});
				</script><div id="para2" printdualcolumn="true"><p>
Appeal from the United States District Court for the Southern District of
Indiana, Richard L. Young, J.
</p></div>
<div id="para2" printdualcolumn="true"><p>
<span CLASS="page_no" data-cite="687 f 3d 1363" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1363" data-primary-citation="687 F.3d 1362">[*1363]</span> 
Kannon Kumar Shanmugam, Williams &amp; Connolly, LLP, of Washington, DC, argued
for plaintiffs-appellees. With him on the brief were Adam L. Perlman, Kannon
K. Shanmugam, Thomas H.L. Selby and Shelley J. Webb.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Robert B. Breisblatt, Katten Muchin Rosenman, LLP, of Chicago, IL, argued
for defendants-appellants. With him on the brief were Craig M. Kuchii, Brian
J. Sodikoff and Thomas J. Maas. Of counsel on the brief was Shashank
Upadhye, Apotex, Inc., of Toronto, Ontario, Canada.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Before PROST, MOORE, and O'MALLEY, Circuit Judges.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
MOORE, Circuit Judge.
</p></div>
<div id="contentOpinion" printdualcolumn="true">
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Apotex Inc. and Apotex Corp. (collectively, Apotex) submitted an
Abbreviated New Drug <span CLASS="page_no" data-cite="103 uspq 2d 1739" data-cite-type="ReporterOfDecisions" data-cite-pageno="1739" data-primary-citation="103 U.S.P.Q.2d 1737">[**1739]</span> Application (ANDA) to the Food and Drug Administration
seeking approval to market a generic version of the anti-allergy eye drop
Patanol&reg;. Alcon Research, Ltd. et al. (collectively, Alcon), who market
Patanol&reg;, sued Apotex for patent infringement under
<a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)(A)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(2)(A). Alcon asserted claims 1-8 of <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/1?citation=U.S.%20Patent%20No.%205,641,805&amp;summary=yes#jcite">U.S. Patent No.
5,641,805</a> (<cite>'805 patent</cite>), which is listed in the Approved Drug Products with
Therapeutic Equivalence Evaluations (Orange Book) entry for Patanol&reg;. For
the reasons set forth below, we <i>reverse</i> the district court's holding that
claims 1-3 and 5-7 would not have been obvious over the prior art but <i>affirm</i>
the court's holding that claims 4 and 8 are not invalid.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  BACKGROUND
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  An allergic reaction is the body's mechanism for expelling antigens, such
as pollen or pet dander. Exposure to an antigen causes the body to produce
antibodies. These antibodies bind to the surface of mast cells, which are
specialized cells that exist in many places in the body and are the primary
cells involved in allergic reactions. This binding sensitizes the mast cells
to that antigen. If the mast cells are subsequently exposed to the same
antigen again, the antigen binds to the antibodies on the surface of the
mast cell. This causes the mast cells to release chemicals called mediators,
such as histamine and heparin. These mediators bind to receptors in
surrounding tissues, triggering the reactions commonly identified as
allergic symptoms, such as itching and redness. In the human eye, mast cells
are located in the conjunctiva, which is the membrane that covers the inner
surface of the eyelid and the white part of the eyeball.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Anti-allergy drugs can treat allergic symptoms by interfering at one of
several points in this process. Antihistamines, for example, prevent the
histamine that is released from mast cells from binding to receptors in
surrounding tissues and also displace the histamine that is already bound to
receptors. By contrast, drugs known as mast cell stabilizers prevent mast
cells from releasing mediators, and <span CLASS="page_no" data-cite="2012 bl 201384 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[***2]</span> thus counteract the effects of histamine
and other mediators that cause allergic symptoms.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The`<cite>805 patent</cite> is directed to a method for treating allergic eye disease
in humans comprising stabilizing conjunctival mast cells by topically
administering an olopatadine<a HREF="#fn100" name="fnref_fn100">[fn1]</a>
<span CLASS="page_no" data-cite="687 f 3d 1364" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1364" data-primary-citation="687 F.3d 1362">[*1364]</span> 
composition.`<cite>805 patent</cite> col.l ll.7-15, col.2 l.64-col.3 l.3. The
specification explains that the discovery that olopatadine can treat human
eye allergies through this mechanism of action &mdash; stabilizing mast cells in
the human eye &mdash; is the novel aspect of the`<cite>805 patent</cite>. <i>See, e.g., <cite>id</cite>.</i> col.2
ll.56-61 ("What is needed are topically administrable drug compounds which
have demonstrated stabilizing activity on mast cells obtained from human
conjunctiva, the target cells for treating allergic eye diseases."); <i>see</i>
<i>also <cite>id</cite>.</i> col.3 ll.18-23 ("[Olopatadine] has human conjunctival mast cell
stabilizing activity, and may be applied as infrequently as once or twice a
day in some cases.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The specification states that at the time of invention, it was already
known in the art that olopatadine was an effective anti-histamine and that
some chemicals in olopatadine's genus may have mast cell stabilizing
activity. <i><cite>Id</cite>.</i> col.1 l.16-col.2 l.61. Indeed, both the olopatadine compound
itself and a method of treating allergies using the class of chemicals that
encompasses olopatadine were both already patented. <i>See</i> <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/X2G84C830OJ?jcsearch=U.S.%20Patent%20No.%205,116,863&amp;summary=yes#jcite">U.S. Patent No.
5,116,863</a>; <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/X2288684GGJ?jcsearch=U.S.%20Patent%20No.%204,923,892&amp;summary=yes#jcite">U.S. Patent No. 4,923,892</a>. The`<cite>805 patent</cite> specification states,
however, that it was not known whether olopatadine would stabilize mast
cells in human eyes. <i><cite>Id</cite>.</i> col.1 ll.43-58. The specification explains that
this was because mast cells in different species, and in different tissues
within the same species, exhibit different biological responses &mdash; a concept
called mast cell heterogeneity. <i><cite>Id</cite>.</i> col.1 ll.43-58. As a result, a
compound's activity in a rodent's conjunctival mast cells or in mast cells
located elsewhere in the human body cannot predict its ability to stabilize
mast cells in the human eye. <i><cite>Id</cite>.</i> col.l l.43 &mdash; col.2 1.19. The`<cite>805 patent</cite>'s
inventors conducted in vitro testing showing that olopatadine stabilizes
conjunctival mast cells in humans.`<cite>805 patent</cite> col.3 11.18-23, col.3
1.43-C01.5 1.55.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The`<cite>805 patent</cite> claims are limited to a method of treating human eye
allergies that <span CLASS="page_no" data-cite="103 uspq 2d 1740" data-cite-type="ReporterOfDecisions" data-cite-pageno="1740" data-primary-citation="103 U.S.P.Q.2d 1737">[**1740]</span> comprises stabilizing conjunctival mast cells. Claim 1 reads:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      A method for treating allergic eye diseases in humans <i>comprising</i>
    <i>stabilizing conjunctival mast cells</i> by topically administering to
    the eye a composition comprising a <i>therapeutically effective amount</i>
    of 11-(3-dimethylaminopropylidene)-6, 11-dihydrodibenz(b,e)
    oxepin-2-acetic acid or a pharmaceutically acceptable salt thereof.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  '<cite>805 patent</cite> col.1 (emphases added). The parties do not dispute the
district court's construction of "stabilizing conjunctival mast cells" as
"preventing or reducing release of mediators including histamine from mast
cells in the conjunctiva to an extent clinically relevant in the treatment
of allergic eye disease." J.A. 176. Although independent claim 1 does not
specify the "therapeutically effective amount" of olopatadine <span CLASS="page_no" data-cite="2012 bl 201384 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[***3]</span> required to
stabilize conjunctival mast cells, dependent claims limit the method of
claim 1 to specific concentration ranges. Claims 2 and 6, for example, are
limited to using a composition that contains from about 0.0001% w/v to about
5% w/v of olopatadine. Claims 4 and 8 are limited to a concentration of 0.1%
w/v of olopatadine.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Alcon's Patanol&reg; product, an anti-allergy eye drop with a 0.1% w/v
concentration of olopatadine, is a commercial embodiment of the`<cite>805 patent</cite>.
Apotex filed an
<span CLASS="page_no" data-cite="687 f 3d 1365" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1365" data-primary-citation="687 F.3d 1362">[*1365]</span> 
ANDA seeking permission to sell a generic version of Patanol&reg; and included a
Paragraph IV certification that the`<cite>805 patent</cite> was invalid, unenforceable,
and/or would not be infringed by Apotex's generic product. Alcon sued Apotex
for patent infringement, asserting claims 1-8. In a bench trial, the
district court held that the`<cite>805 patent</cite> was enforceable and not invalid, and
that Apotex's generic product in-fringed the asserted claims. <i>Alcon</i>
<i>Research, Ltd. v. Apotex Inc.</i>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/X1FG9MS003?jcsearch=790%20f%20supp%202d%20868&amp;summary=yes#jcite">790 F.Supp.2d 868</a>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/X1FG9MS003?jcsearch=790%20f%20supp%202d%20868&amp;summary=yes#jcite">944-45</a> (S.D.Ind.2011).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On the issue of validity, the district court held that Apotex failed to
establish that the claims would have been obvious by clear and convincing
evidence. The court recognized that olopatadine was known to be an effective
antihistamine, but found that at the time of invention a skilled artisan
"understood that there were significant barriers to adapting a known
systemic antihistamine for topical use in the eye." <i></i><a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/X1FG9MS003?jcsearch=790%20F.%20Supp.%202d%20868&amp;summary=yes#jcite">Id. at 877</a>. The court
also found that the prior art as a whole, and specifically an article by
Kamei et al, taught away from using olopatadine as a mast cell stabilizer.
Kamei tested an ophthalmic formulation of olopatadine in guinea pig eyes at
concentrations that overlap with those recited in most of the`<cite>805 patent</cite>
claims. Kamei discloses that, although olopatadine is a good antihistamine,
it is not an effective mast cell stabilizer. J.A. 10162-63. The court
further found that Kamei's disclosure of using olopatadine eye drops in
guinea pigs would not give a skilled artisan an expectation of success
because it does not show whether olopatadine is safe to use in the human
eye. The district court rejected Apotex's argument that the prior art need
not teach mast cell stabilization because this mechanism of action is an
inherent property of olopatadine. In reaching this conclusion, the court
relied largely on testimony by Alcon's expert, Dr. Kaliner, that not every
concentration of olopatadine will stabilize human conjunctival mast cells to
a "clinically relevant" extent, as required by the court's claim
construction.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court also held that objective evidence supported its holding
of non-obviousness. For example, the court found that Patanol&reg; showed
unexpected results because a person of ordinary skill would not have
expected it to be an effective mast cell stabilizer in the human eye. <i>Alcon</i>
<i>v. Apotex</i>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/X1FG9MS003?jcsearch=790%20F.%20Supp.%202d%20868&amp;summary=yes#jcite">790 F.Supp.2d at 905</a>. The court concluded that Patanol&reg; satisfied
a long-felt but unmet need for a human conjunctival mast cell stabilizer.
The court further found that Patanol&reg; has been "an outstanding commercial
success," achieving nearly a 70% market share within two years <span CLASS="page_no" data-cite="2012 bl 201384 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[***4]</span> of its
launch. <i></i><a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/X1FG9MS003?jcsearch=790%20F.%20Supp.%202d%20868&amp;summary=yes#jcite">Id. at 904</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Apotex now appeals from the district court's final judgment that the`<cite>805
patent</cite> would not have been obvious over the prior art and from the grant of
a permanent injunction barring Apotex from selling its generic product. We
have jurisdiction under <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/XEIMUG003?jcsearch=28%20U.S.C.%20%201295(a)(1)&amp;summary=yes#jcite">28 U.S.C. &sect; 1295</a>(a)(1).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  DISCUSSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A patent is invalid for obviousness "if the differences between the
subject matter sought to be patented and the prior art are such that the
subject matter as a whole would have been obvious at the time the invention
was made to a person having ordinary skill in the art to which said subject
matter pertains." <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/XEIVVE003?jcsearch=35%20U.S.C.%20%20103(a)&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a>(a). "Obviousness is a question of law,
which we review <i>de novo</i>, with underlying factual questions, which we review
for clear <span CLASS="page_no" data-cite="103 uspq 2d 1741" data-cite-type="ReporterOfDecisions" data-cite-pageno="1741" data-primary-citation="103 U.S.P.Q.2d 1737">[**1741]</span> error following a bench trial." <i>Honeywell Int'l Inc. v. United</i>
<i>States</i>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/X1DAEEM003?jcsearch=609%20f%203d%201292&amp;summary=yes#jcite">609 F.3d 1292</a>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/X1DAEEM003?jcsearch=609%20f%203d%201292&amp;summary=yes#jcite">1297</a> (Fed.Cir.2010). These underlying factual
inquires are: (1) the scope and content of the prior art; (2) the
differences between the prior art and the claims
<span CLASS="page_no" data-cite="687 f 3d 1366" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1366" data-primary-citation="687 F.3d 1362">[*1366]</span> 
at issue; (3) the level of ordinary skill in the field of the invention; and
(4) objective considerations such as commercial success, long felt need, and
the failure of others. <i>KSR Int'l Co. v. Teleflex, Inc.</i>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">550 U.S. 398</a>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">406</a>,
<a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/1?citation=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/XRIK7VQNB5G0?jcsearch=167%20l%20ed%202d%20705&amp;summary=yes#jcite">167 L.Ed.2d 705</a> (2007) (citing <i>Graham v. John Deere Co. of</i>
<i>Kan. City</i>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/X5C6EI?jcsearch=383%20us%201&amp;summary=yes#jcite">383 U.S. 1</a>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/X5C6EI?jcsearch=383%20us%201&amp;summary=yes#jcite">17-18</a>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/1?citation=86%20supreme%20court%20684&amp;summary=yes#jcite">86 S.Ct. 684</a>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/X5C6EI?jcsearch=15%20l%20ed%202d%20545&amp;summary=yes#jcite">15 L.Ed.2d 545</a> (1966)). Patent
invalidity must be established by clear and convincing evidence. <i>Microsoft</i>
<i>Corp. v. i4i Ltd.</i>, <cite>___ U.S. ___</cite>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/X1FI916003?jcsearch=131%20supreme%20court%202238&amp;summary=yes#jcite">131 S.Ct. 2238</a>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/X1FI916003?jcsearch=131%20supreme%20court%202238&amp;summary=yes#jcite">2242</a>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/X1FI916003?jcsearch=180%20l%20ed%202d%20131&amp;summary=yes#jcite">180 L.Ed.2d 131</a>
(2011).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I. Claims 1-3 and 5-7
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Apotex argues that the district court erred by finding that the`805 patent
claims would not have been obvious over the prior art. Apotex asserts that
claims 1-3 and 5-7 would have been obvious over Kamei, which discloses eye
drops with olopatadine concentrations that overlap with the claimed
concentration ranges. Apotex argues that even though Kamei tested
olopatadine formulations only in guinea pig eyes, a person of ordinary skill
in the art could use routine methods to adapt these formulations for human
use with a reasonable expectation of success. Apotex also argues that the
district court erred by focusing on Kamei's lack of disclosure that
olopatadine is safe for human use because the`805 claims do not recite a
"safety" limitation.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Apotex contends that the district court erred by requiring that the prior
art provide a motivation to use olopatadine specifically as a mast cell
stabilizer. Apotex argues that the prior art's disclosure that olopatadine
is an effective antihistamine that can be formulated for ophthalmic use
provides sufficient motivation to develop an olopatadine eye drop for
humans. Apotex also argues that claiming olopatadine's mechanism of action
(stabilizing conjunctival mast cells) cannot impart patentability to the`805
patent claims because it is an inherent property of olopatadine. Apotex also
asserts that even if this limitation restricts the claims to certain
concentrations of olopatadine, the claims nonetheless would have been
obvious because the prior art teaches using olopatadine at those
concentrations.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Apotex also argues that the district court erred by finding that objective
evidence supported its holding of nonobviousness. Specifically, Apotex
contends that olopatadine'<span CLASS="page_no" data-cite="2012 bl 201384 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[***5]</span> s superior clinical efficacy is due at least in
part to its antihistaminic activity, which is not a novel aspect of the`805
patent. Apotex thus argues that the district court's findings regarding
commercial success, industry praise, and unexpected results lack sufficient
nexus to the`805 patent claims.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Alcon contends that the court correctly found that a skilled artisan would
not be motivated to formulate an olopatadine eye drop solely based on its
antihistaminic activity because the prior art does not supply a reason to
focus on olopatadine instead of many other promising antihistamines. Alcon
also argues that the court correctly found that there would not have been a
reasonable expectation of success in formulating an olopatadine eye drop
because, at the time of invention, there were barriers to adapting an oral
antihistamine for ophthalmic use.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Alcon does not dispute that Kamei teaches using olopatadine eye drops at
concentrations that overlap with those in claims 1-3 and 5-7 of the`805
patent. Instead, Alcon argues that Kamei does not teach that olopatadine
would be a mast cell stabilizer at those concentrations or that it would be
safe for use in the human eye. Alcon argues that the district court
correctly found that the prior art as a whole teaches away from using
olopatadine as a mast cell stabilizer. Alcon also asserts
<span CLASS="page_no" data-cite="687 f 3d 1367" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1367" data-primary-citation="687 F.3d 1362">[*1367]</span> 
that the district court correctly found that mast cell stabilization is not
an inherent property of olopatadine because only some concentrations
stabilize mast cells to a clinically relevant extent, as required by the
court's claim construction. Finally, Alcon argues that the district court
correctly found that objective evidence supports a finding of
nonobviousness.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As an initial matter, we believe the district court erred in its
comparison of the`805 patent claims and the disclosure of the prior art.
Claim 1 recites a method of treating allergic eye disease comprising using a
"therapeutically effective amount" of olopatadine to stabilize conjunctival
mast cells. The court construed the term "stabilizing conjunctival mast
cells" to limit the claims only to concentrations of olopatadine that
stabilize conjunctival mast cells "to an extent clinically relevant in the
treatment of allergic eye disease." J.A. 176. This construction is not
appealed. Because <span CLASS="page_no" data-cite="103 uspq 2d 1742" data-cite-type="ReporterOfDecisions" data-cite-pageno="1742" data-primary-citation="103 U.S.P.Q.2d 1737">[**1742]</span> it is not appealed, we do not decide whether this
construction is correct.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On appeal, however, we must determine what olopatadine concentrations
constitute a "therapeutically effective amount." The dependent claims are a
starting point for ascertaining the concentration of olopatadine covered by
claim 1. Claim 2, for example, is directed to the method of claim 1 wherein
"the amount of [olopatadine] is from about 0.0001 w/v. % to about 5% (w/v)."
Claim 3 further narrows the range to "about 0.001 to about 0.2% (w/v)."
Claim 4 further narrows the range to "about 0.1% (w/v)." As far as the
concentrations of olopatadine, claims 5-8 mirror the ranges disclosed in
1-4, respectively.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_924800" href="#headnote_pq2-dec_924800">[1]</a> It is axiomatic that a dependent claim cannot be broader than the <span CLASS="page_no" data-cite="2012 bl 201384 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[***6]</span> claim
from which it depends. <i>See</i><a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/1?citation=35%20usc%20112&amp;summary=yes#jcite">35 U.S.C. &sect; 112</a> &para; 4 ("[A] claim in dependent form
shall contain a reference to a claim previously set forth and then specify a
further limitation of the subject matter claimed."); <i>see also Intamin Ltd.</i>
<i>v. Magnetar Techs., Corp.</i>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/1?citation=483%20f%203d%201328&amp;summary=yes#jcite">483 F.3d 1328</a>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/1?citation=483%20f%203d%201328&amp;summary=yes#jcite">1335</a> (Fed.Cir.2007) ("An
independent claim impliedly embraces more subject matter than its narrower
dependent claim."); <i>AK Steel Corp. v. Sollac &amp; Ugine</i>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/1?citation=344%20f%203d%201234&amp;summary=yes#jcite">344 F.3d 1234</a>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/1?citation=344%20f%203d%201234&amp;summary=yes#jcite">1242</a>
(Fed.Cir.2003) ("Under the doctrine of claim differentiation, dependent
claims are presumed to be of narrower scope than the independent claims from
which they depend."). Therefore if claim 2 covers the range from 0.0001%
w/v-5% w/v, claim 1 must cover at least that range. Furthermore, because a
dependent claim narrows the claim from which it depends, it must
"incorporate . . . all the limitations of the claim to which it refers."
<a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/1?citation=35%20usc%20112&amp;summary=yes#jcite">35 U.S.C. &sect; 112</a> &para; 4. As a result, the concentrations recited in the`805
patent's dependent claims must necessarily meet claim l's limitations of
being therapeutically effective for treating allergic eye disease by
stabilizing conjunctival mast cells. This is clear from the express claim
language. It is also supported by the specification: "The concentration of
Compound A is 0.0001 to 5 w/v %, preferably 0.001 to 0.2 w/v %, and most
preferably about 0.1 w/v %. . . . "`805 patent col.6 ll.43-46.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Despite the clear language of the`805 patent claims, Alcon argues that
some olopatadine concentrations covered by claims 1-3 and 5-7 do <i>not</i>
stabilize human conjunctival mast cells to a clinically relevant extent and
should therefore be excluded from the claims' scope. The district court
found that "[n]ot every concentration of olopatadine applied to the human
eye will stabilize the mast cells in the human eye." <i>Alcon v. Apotex</i>,
<a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/1?citation=790%20f%20supp%202d%20868&amp;summary=yes#jcite">790 F.Supp.2d at 909</a>. The court cited testimony by Alcon's expert, Dr.
Kaliner, that olopatadine at 0.001% w/v (which is covered by claims 1-3 and
5-7) would not stabilize human conjunctival
<span CLASS="page_no" data-cite="687 f 3d 1368" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1368" data-primary-citation="687 F.3d 1362">[*1368]</span> 
mast cells to a clinically relevant extent. <i>Id.</i> at 909, 935.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Alcon's counsel argued that, "to the extent that the dependent claims
cover a broader range than the range that would be operative to stabilize
mast cells," the inoperative portion of the range "wouldn't be covered by
the claim by virtue of the limitation in claim 1" that mast cell
stabilization must occur to a clinically relevant extent. Argument at
14:56-15:22, <i>Alcon Research v. Apotex</i>, No. 2011-1455, available at
http://oralarguments.cafc.uscourts. gov/default.aspx?fl=2011-1455.mp3.
Alcon's counsel thus contended that the claims "would be operative, just at
a narrower concentration" than the claimed range. <i>Id.</i> at 15:24-15:27. This
is not how patent law works. When you claim a concentration range of
0.0001-5% w/v (as claim 2), you can't simply disavow the invalid portion and
keep the valid portion of the claim. If everything up to 0.001% w/v is
admittedly not enabled, then the entire claim is invalid. Similarly, if
prior art discloses a portion of the claimed range, the entire claim is
invalid. Courts do not rewrite the claims to narrow them for the patentee to
cover only the valid portion. Alcon cannot have it both ways. Because claim
2 sets forth a concentration range, that range at a minimum must <span CLASS="page_no" data-cite="2012 bl 201384 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[***7]</span> be included
in claim 1, whatever its limitations. When analyzing the validity of claim 1
or claim 2, by the express claim language, the clinically relevant
therapeutic amount must include 0.0001-5% w/v olopatadine. That is the
claimed concentration range which should be compared to the disclosure of
the prior art.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_924801" href="#headnote_pq2-dec_924801">[2]</a> The Kamei reference discloses treating eye allergies in guinea pigs using
eye drops with olopatadine concentrations ranging from 0.0001% w/v to 0.01%
w/v. J.A. 10160-63. This range overlaps with the concentrations covered by
claims 1-3 and 5-7. Claims 4 and 8 are directed only to a 0.1% olopatadine
formulation, and Kamei does not disclose a concentration <span CLASS="page_no" data-cite="103 uspq 2d 1743" data-cite-type="ReporterOfDecisions" data-cite-pageno="1743" data-primary-citation="103 U.S.P.Q.2d 1737">[**1743]</span> of olopatadine
greater than 0.01%. Kamei expressly discloses eye drops with olopatadine
concentrations covered by claims 1-3 and 5-7 and thus overlaps with the
ranges disclosed in the`805 patent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The only remaining dispute is whether there was a motivation to adapt the
formulation disclosed in Kamei, which was tested in guinea pigs, for use in
treating allergic eye disease in humans. The district court found, as a
factual matter, that animal tests, including guinea pig models, are
predictive of a compound's antihistaminic activity and its topical ocular
availability in humans. <i>Alcon v. Apotex</i>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/1?citation=790%20f%20supp%202d%20868&amp;summary=yes#jcite">790 F.Supp.2d at 881</a>. Given this
fact finding, the district court clearly erred when it concluded that a
person of skill in the art would not have been motivated to use the
olopatadine concentration disclosed in Kamei in human eyes. The district
court's error stemmed from its refusal to look at any motivation beyond that
articulated by the patent. We have repeatedly held that the motivation to
modify a prior art reference to arrive at the claimed invention need not be
the same motivation that the patentee had. See <i>KSR</i>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/1?citation=550%20us%20398&amp;summary=yes#jcite">550 U.S. at 420</a>,
<a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/1?citation=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a> (stating that it is error to look "only to the problem the
patentee was trying to solve"); <i>see also In re Kahn</i>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/1?citation=441%20f%203d%20977&amp;summary=yes#jcite">441 F.3d 977</a>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/1?citation=441%20f%203d%20977&amp;summary=yes#jcite">990</a>
(Fed.Cir.2006) ("[T]he skilled artisan need not be motivated to combine [the
prior art] for the same reason contemplated by [the inventor]." (citing <i>In</i>
<i>re Beattie</i>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/1?citation=974%20f%202d%201309&amp;summary=yes#jcite">974 F.2d 1309</a>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/1?citation=974%20f%202d%201309&amp;summary=yes#jcite">1312</a> (Fed.Cir.1992) ("[T]he law does not require
that the references be combined for the reasons contemplated by the
inventor."))); <i>DyStar Textilfarben GmbH v. C.H. Patrick Co.</i>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/1?citation=464%20f%203d%201356&amp;summary=yes#jcite">464 F.3d 1356</a>,
<a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/1?citation=464%20f%203d%201356&amp;summary=yes#jcite">1361</a> (Fed.Cir.2006) (stating that the motivation to modify the prior art to
arrive at the claimed invention "may be found in any number of sources,
including common
<span CLASS="page_no" data-cite="687 f 3d 1369" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1369" data-primary-citation="687 F.3d 1362">[*1369]</span> 
knowledge, the prior art as a whole, or the nature of the problem itself.").
Here, the motivation to adapt Kamei's formulation for human use is that it
is an effective antihistamine in guinea pigs and that animals models are (as
the district court expressly found) predictive of antihistaminic efficacy in
humans.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court's fact finding that the prior art did not teach that
olopatadine would stabilize human conjunctival mast cells, and indeed taught
away from using olopatadine for this purpose, is not clearly erroneous. It
is, however, not the only motivation to arrive at the claimed invention. A
person of ordinary skill in the art at the time of invention would have been
motivated to use olopatadine to treat human eye <span CLASS="page_no" data-cite="2012 bl 201384 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[***8]</span> allergies as claimed for its
established antihistaminic efficacy. Given that the patent defines, and
expressly claims, olopatadine concentrations that are "therapeutically
effective" to stabilize conjunctival mast cells, Kamei's disclosure of
overlapping concentrations, even if for a different purpose, meets these
claim limitations.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Although Alcon argues that Kamei would not give a skilled artisan an
expectation of success because it does not teach that olopatadine is safe
for the human eye, we find this contention to be without merit. <i>Id.</i> While it
is true that Kamei does not expressly disclose that olopatadine would be
safe for use in human eyes, neither does the`805 patent. The patent is not
based on testing in humans; instead it reports only <i>in vitro</i> tests of
olopatadine in human conjunctival mast cells.`805 patent col.3 l.43-col.4
l.24. We conclude that, just as a skilled artisan would be able to practice
the invention claimed in the`805 patent despite its lack of explicit
instruction that olopatadine is safe for human ophthalmic use, the artisan
would have a reasonable expectation of success for adapting Kamei's
formulation for the same use in a human eye.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The parties dispute whether stabilizing conjunctival mast cells is an
inherent property of olopatadine and whether inherency may be used in an
obviousness analysis. We addressed a similar situation in <i>In re Kubin</i>, where
we explained that, "[e]ven if no prior art of record explicitly discusses
the [limitation], the [patent applicant's] application itself instructs that
[the limitation] is not an additional requirement imposed by the claims on
the [claimed invention], but rather a property necessarily present in the
[claimed invention]." <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/1?citation=561%20f%203d%201351&amp;summary=yes#jcite">561 F.3d 1351</a>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/1?citation=561%20f%203d%201351&amp;summary=yes#jcite">1357</a> (Fed.Cir. 2009). The same is true
here. The district court's construction of "stabilizing conjunctival mast
cells" restricts the claims to certain olopatadine concentrations. As in <i>In</i>
<i>re Kubin</i>, this claim language does not impose any additional requirement
because the`805 patent itself defines mast cell stabilization as a property
that is necessarily present at those concentrations.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Kamei expressly discloses using olopatadine eye drops to treat eye
allergies at concentrations <span CLASS="page_no" data-cite="103 uspq 2d 1744" data-cite-type="ReporterOfDecisions" data-cite-pageno="1744" data-primary-citation="103 U.S.P.Q.2d 1737">[**1744]</span> that overlap with those in claims 1-3 and 5-7 of
the`805 patent and thus meets the "stabilizing conjunctival mast cells"
limitation. Moreover, Kamei would give a person of ordinary skill in the art
an expectation of success for using olopatadine to treat human eye
allergies. We therefore conclude that the district court erred in its
determination that there was no prima facie case of obviousness based on
Kamei.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On appeal, Alcon argues that objective considerations support the district
court's conclusion of nonobviousness. We weigh these objective
considerations along with the other parts of the obviousness analysis to
determine <i>de novo</i> whether the claims would have been obvious to one of skill
in
<span CLASS="page_no" data-cite="687 f 3d 1370" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1370" data-primary-citation="687 F.3d 1362">[*1370]</span> 
the art. We see no clear error in the district court's fact findings, but
conclude after balancing the objective evidence against the strong <span CLASS="page_no" data-cite="2012 bl 201384 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[***9]</span> evidence
of obviousness discussed above, that Apotex has established by clear and
convincing evidence that claims 1-3 and 5-7 would have been obvious to one
of ordinary skill in the art over Kamei, which discloses every limitation of
these claims except that the formulation can be used to treat eye allergies
in humans. We have considered all of Alcon's arguments regarding these
claims and find them to be without merit.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  II. Claims 4 and 8
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  While Kamei renders claims 1-3 and 5-7 obvious because it discloses
olopatadine concentrations that overlap with the ranges in those claims, it
does not teach the 0.1% w/v composition recited in claims 4 and 8 of the`805
patent, Apotex argues that even though Kamei does not disclose the claimed
0.1% w/v concentration, routine experimentation would have led a skilled
artisan to try this formulation. Apotex contends that because Kamei's
testing showed that antihistaminic efficacy increased as olopatadine
concentration increased from 0.0001% w/v to 0.01% w/v, it would be logical
to try a 0.1% formulation. Apotex also argues that a skilled artisan would
rely on U.S. Patent No. 4,923,892 (Lever) as guidance for formulating a 0.1%
w/v eye drop. Lever claims a class of chemical compounds that includes
olopatadine and a method of treating allergies in animals by using this
class of compounds. <i>See, e.g.</i>,`892 patent col.1, 7. One example in Lever
teaches an ophthalmic solution containing 0.1% w/v of a different active
compound (i.e., <i>not</i> olopatadine). <i>Id.</i> col.17 ll.20-25, col. 19 ll.5-13.
Apotex argues that a skilled artisan would simply modify this 0.1% w/v
formulation by substituting olopatadine for the other active compound at the
same concentration.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Alcon contends that neither Kamei nor Lever would have motivated a person
of ordinary skill in the art to try a 0.1% w/v olopatadine formulation.
Alcon cites the district court's finding that a skilled artisan would have
expected olopatadine to be "biphasic," or to stabilize mast cells below a
certain concentration but destabilize them above that concentration. Alcon
argues that the court correctly determined that the potential to destabilize
mast cells would have led a skilled artisan not to try higher concentrations
of olopatadine than those disclosed in Kamei. Alcon also argues that the
district court correctly found that a skilled artisan could not simply
substitute olopatadine into the ophthalmic solution disclosed in Lever at
the same concentration, and thus that Lever does not teach using olopatadine
at 0.1% w/v.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_924802" href="#headnote_pq2-dec_924802">[3]</a> We have considered all of Apotex's arguments and conclude that the
district court correctly held that claims 4 and 8 of the`805 patent would
not have been obvious. These claims are limited to using formulations with
an olopatadine concentration of about 0.1% w/v. Kamei, however, only tested
formulations with olopatadine concentrations up to 0.01% w/v and thus does
not disclose this limitation. We cannot say the district court clearly erred
by finding that Kamei does not teach or suggest using olopatadine at a
concentration of 0.1% w/v. As the court noted, the <span CLASS="page_no" data-cite="2012 bl 201384 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[***10]</span> concentrations tested in
Kamei were substantially lower than 0.1%. The court relied on expert
testimony that a person of ordinary skill in the art would not have a
reasonable expectation of success for increasing the highest dosage used in
Kamei by an order of magnitude. <i>Alcon v. Apotex</i>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/1?citation=790%20f%20supp%202d%20868&amp;summary=yes#jcite">790 F.Supp.2d at 894</a>
(citing J.A. 21759-60). We also agree with the court that a person of
ordinary skill in the art would have been concerned that olopatadine might
be biphasic at this increased concentration, and
<span CLASS="page_no" data-cite="687 f 3d 1371" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1371" data-primary-citation="687 F.3d 1362">[*1371]</span> 
thus would not have tried a formulation with ten times more olopatadine than
the highest dosage used in Kamei. <i>Id.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Moreover, the court did not clearly err by finding that a skilled artisan
would not arrive at a 0.1% w/v olopatadine eye drop by substituting
olopatadine for the active compound <span CLASS="page_no" data-cite="103 uspq 2d 1745" data-cite-type="ReporterOfDecisions" data-cite-pageno="1745" data-primary-citation="103 U.S.P.Q.2d 1737">[**1745]</span> used in the ophthalmic formulation
disclosed in Lever. As the district court explained, a person of ordinary
skill in the art would have known that one could not simply substitute one
active ingredient for another without adjusting the concentration. <i>Id.</i> at
900. The court thus correctly found that Lever does not teach an ophthalmic
formulation with an olopatadine concentration of 0.1% w/v.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Objective evidence further supports the district court's holding that
claims 4 and 8 would not have been obvious. The district court's fact
findings regarding the objective considerations are not clearly erroneous.
The court found that Patanol&reg; was "an outstanding commercial success,"
achieving nearly 70% market share within two years of its launch, accounting
for nearly $2 billion in sales within ten years, and garnering wide-spread
praise within the industry. <i>Id.</i> at 904. The 0.1% w/v olopatadine
concentration recited in claims 4 and 8 is the same as is used in Patanol&reg;.
As a result, with respect to claims 4 and 8, Alcon's objective evidence
demonstrates that "the commercial success was caused by the merits of the
invention as distinct from the prior art." <i>In re Kao</i>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/1?citation=639%20f%203d%201057&amp;summary=yes#jcite">639 F.3d 1057</a>, <a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/1?citation=639%20f%203d%201057&amp;summary=yes#jcite">1069</a>
(Fed.Cir.2011). Because Alcon failed to prove by clear and convincing
evidence that a 0.1% w/v olopatadine formulation would have been obvious
over the prior art, we conclude the district court correctly held that
claims 4 and 8 would not have been obvious.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  CONCLUSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In view of the foregoing, we reverse the district court's holding that
claims 1-3 and 5-7 of the`805 patent would not have been obvious. We affirm
its holding that claims 4 and 8 would not have been obvious.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  REVERSED-IN-PART, AFFIRMED-IN-PART
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  COSTS
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  No costs.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> The method claimed in the`805 patent uses the compound
11-(3-dimethylaminopropylidene)-6, 11-dihydrodibenz(b,e) oxepin-2-acetic
acid or a pharmaceutically acceptable salt thereof. Although this compound
has two geometric isomers (a cis and a trans form), we refer to these
compounds throughout this opinion simply as olopatadine (the cis form).
</p></div>
</div>
<!--BBLS DD 1721204080643-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1I2VS4003/history">Direct History (6)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1I2VS4003/analysis">Case Analysis (3)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1I2VS4003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
3
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Judgment Affirmed (In Part), Judgment Reversed (In Part)</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Health &amp; Medical</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/536878859f55c280da77bc1b3c141737/document/X1Q6LL8UN882">11-01455 (Fed. Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Patent Law</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/536878859f55c280da77bc1b3c141737/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "536878859f55c280da77bc1b3c141737";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY7fd641&previousPageId=&previousActivityInstanceId=ENTITYe38342&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T07:12:52-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1I2VS4003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITYe38342&previousPageId=&previousActivityInstanceId=ENTITYebd663&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T07:12:31-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1I2VS4003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1I2VS4003";
$('#page_loader').show().spin();
JUDGE_IDS=["15753020","3057465","4063892"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
